TAOX
TAO Synergies Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
TAO Synergies Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for TAO Synergies Inc..
Same SIC code · 6
Same SEC industry code: American Express Co, Coinbase Global, Inc., Synchrony Financial and 3 more; no measured co-movers for TAO Synergies Inc..
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
No trades yet today.
No trades yet today.
TAO Synergies Inc.
2.66
pre 2.98 +11.61%
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $441,897 | 16.64% | +49.27% |
| Citadel | $310,231 | 11.68% | new |
| Geodeindex-like | $296,264 | 11.15% | −10.46% |
| Renaissance Technologies | $293,987 | 11.07% | −22.58% |
| Summit Financial | $215,445 | 8.11% | +33.47% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $441,897 | 16.64% | +49.27% |
| Citadel | $310,231 | 11.68% | new |
| Geodeindex-like | $296,264 | 11.15% | −10.46% |
| Renaissance Technologies | $293,987 | 11.07% | −22.58% |
| Summit Financial | $215,445 | 8.11% | +33.47% |
Bull0
—
Bear2